The Experts below are selected from a list of 2703 Experts worldwide ranked by ideXlab platform
Yidong Chen - One of the best experts on this subject based on the ideXlab platform.
-
cDNA Microarray Technology and its applications
Biotechnology advances, 2000Co-Authors: Charlie C. Xiang, Yidong ChenAbstract:The cDNA Microarray is the most powerful tool for studying gene expression in many different organisms. It has been successfully applied to the simultaneous expression of many thousands of genes and to large-scale gene discovery, as well as polymorphism screening and mapping of genomic DNA clones. It is a high throughput, highly parallel RNA expression assay technique that permits quantitative analysis of RNAs transcribed from both known and unknown genes. This technique provides diagnostic fingerprints by comparing gene expression patterns in normal and pathological cells, and because it can simultaneously track expression levels of many genes, it provides a source of operational context for inference and predication about complex cell control systems. This review describes this recently developed cDNA Microarray Technology and its application to gene discovery and expression, and to diagnostics for certain diseases.
-
Molecular pathophysiologic hints into Niemann-Pick Type C disease using cDNA Microarray Technology
Nature Genetics, 1999Co-Authors: Dietrich A. Stephan, David O. Azorsa, David Duggan, Lindsay Malechek, C. Gooden, M. Bittner, Yidong Chen, Paul S. Meltzer, J.m. Trent, Melissa A. AshlockAbstract:Molecular pathophysiologic hints into Niemann-Pick Type C disease using cDNA Microarray Technology
-
hormone therapy failure in human prostate cancer analysis by complementary dna and tissue Microarrays
Journal of the National Cancer Institute, 1999Co-Authors: Lukas Bubendorf, Yidong Chen, Meelis Kolmer, Juha Kononen, Pasi A Koivisto, Spyro Mousses, Eija Mahlamaki, Peter Schraml, Holger MochAbstract:Background: The molecular mechanisms underlying the progression of prostate cancer during hormonal therapy have remained poorly understood. In this study, we developed a new strategy for the identification of differentially expressed genes in hormone-refractory human prostate cancer by use of a combination of complementary DNA (cDNA) and tissue Microarray technologies. Methods: Differences in gene expression between hormone-refractory CWR22R prostate cancer xenografts (human prostate cancer transplanted into nude mice) and a xenograft of the parental, hormone-sensitive CWR22 strain were analyzed by use of cDNA Microarray Technology. To validate the data from cDNA Microarrays on clinical prostate cancer specimens, a tissue Microarray of specimens from 26 prostates with benign prostatic hyperplasia, 208 primary prostate cancers, and 30 hormone-refractory local recurrences was constructed and used for immunohistochemical detection of protein expression. Results: Among 5184 genes surveyed with cDNA Microarray Technology, expression of 37 (0.7%) was increased more than twofold in the hormone-refractory CWR22R xenografts compared with the CWR22 xenograft ; expression of 135 (2.6%) genes was reduced by more than 50%. The genes encoding insulin-like growth factor-binding protein 2 (IGFBP2) and 27-kd heat-shock protein (HSP27) were among the most consistently over-expressed genes in the CWR22R tumors. Immunohistochemical analysis of tissue Microarrays demonstrated high expression of IGFBP2 protein in 100% of the hormone-refractory clinical tumors, in 36% of the primary tumors, and in 0% of the benign prostatic specimens (two-sided P = .0001). Overexpression of HSP27 protein was demonstrated in 31% of the hormone-refractory tumors, in 5% of the primary tumors, and in 0% of the benign prostatic specimens (two-sided P = .0001). Conclusions: The combination of cDNA and tissue Microarray technologies enables rapid identification of genes associated with progression of prostate cancer to the hormone-refractory state and may facilitate analysis of the role of the encoded gene products in the pathogenesis of human prostate cancer.
-
gene expression profiling of alveolar rhabdomyosarcoma with cDNA Microarrays
Cancer Research, 1998Co-Authors: Javed Khan, Yidong Chen, Richard Simon, Michael L Bittner, Stephen B Leighton, Thomas J Pohida, Paul Smith, Yuan Jiang, Gerald C Gooden, Jeffrey M. TrentAbstract:Several forms of human sarcoma, lymphoma, and leukemia are characterized by somatically acquired chromosome translocations that result in fusion genes that encode chimeric transcription factors with oncogenic properties. We have used cDNA Microarrays containing 1238 cDNAs to investigate the gene expression profile of a group of seven alveolar rhabdomyosarcoma (ARMS) cell lines characterized by the presence of the PAX3-FKHR fusion gene. Using the method of multidimensional scaling to represent the relationships among the cell lines in two-dimensional Euclidean space, we determined that ARMS cells show a consistent pattern of gene expression, which allows the cells to be clustered together. By searching across the seven ARMS cell lines, we found that 37 of 1238 genes were most consistently expressed in ARMS relative to a reference cell line. Only three of these genes have been previously reported to be expressed in ARMS. Among these 37 were genes related to both primary (PAX3-FKHR) and secondary (CDK4) genetic alterations in ARMS. These results in ARMS demonstrate the potential of cDNA Microarray Technology to elucidate tumor-specific gene expression profiles in human cancers.
Holger Moch - One of the best experts on this subject based on the ideXlab platform.
-
hormone therapy failure in human prostate cancer analysis by complementary dna and tissue Microarrays
Journal of the National Cancer Institute, 1999Co-Authors: Lukas Bubendorf, Yidong Chen, Meelis Kolmer, Juha Kononen, Pasi A Koivisto, Spyro Mousses, Eija Mahlamaki, Peter Schraml, Holger MochAbstract:Background: The molecular mechanisms underlying the progression of prostate cancer during hormonal therapy have remained poorly understood. In this study, we developed a new strategy for the identification of differentially expressed genes in hormone-refractory human prostate cancer by use of a combination of complementary DNA (cDNA) and tissue Microarray technologies. Methods: Differences in gene expression between hormone-refractory CWR22R prostate cancer xenografts (human prostate cancer transplanted into nude mice) and a xenograft of the parental, hormone-sensitive CWR22 strain were analyzed by use of cDNA Microarray Technology. To validate the data from cDNA Microarrays on clinical prostate cancer specimens, a tissue Microarray of specimens from 26 prostates with benign prostatic hyperplasia, 208 primary prostate cancers, and 30 hormone-refractory local recurrences was constructed and used for immunohistochemical detection of protein expression. Results: Among 5184 genes surveyed with cDNA Microarray Technology, expression of 37 (0.7%) was increased more than twofold in the hormone-refractory CWR22R xenografts compared with the CWR22 xenograft ; expression of 135 (2.6%) genes was reduced by more than 50%. The genes encoding insulin-like growth factor-binding protein 2 (IGFBP2) and 27-kd heat-shock protein (HSP27) were among the most consistently over-expressed genes in the CWR22R tumors. Immunohistochemical analysis of tissue Microarrays demonstrated high expression of IGFBP2 protein in 100% of the hormone-refractory clinical tumors, in 36% of the primary tumors, and in 0% of the benign prostatic specimens (two-sided P = .0001). Overexpression of HSP27 protein was demonstrated in 31% of the hormone-refractory tumors, in 5% of the primary tumors, and in 0% of the benign prostatic specimens (two-sided P = .0001). Conclusions: The combination of cDNA and tissue Microarray technologies enables rapid identification of genes associated with progression of prostate cancer to the hormone-refractory state and may facilitate analysis of the role of the encoded gene products in the pathogenesis of human prostate cancer.
Meelis Kolmer - One of the best experts on this subject based on the ideXlab platform.
-
hormone therapy failure in human prostate cancer analysis by complementary dna and tissue Microarrays
Journal of the National Cancer Institute, 1999Co-Authors: Lukas Bubendorf, Yidong Chen, Meelis Kolmer, Juha Kononen, Pasi A Koivisto, Spyro Mousses, Eija Mahlamaki, Peter Schraml, Holger MochAbstract:Background: The molecular mechanisms underlying the progression of prostate cancer during hormonal therapy have remained poorly understood. In this study, we developed a new strategy for the identification of differentially expressed genes in hormone-refractory human prostate cancer by use of a combination of complementary DNA (cDNA) and tissue Microarray technologies. Methods: Differences in gene expression between hormone-refractory CWR22R prostate cancer xenografts (human prostate cancer transplanted into nude mice) and a xenograft of the parental, hormone-sensitive CWR22 strain were analyzed by use of cDNA Microarray Technology. To validate the data from cDNA Microarrays on clinical prostate cancer specimens, a tissue Microarray of specimens from 26 prostates with benign prostatic hyperplasia, 208 primary prostate cancers, and 30 hormone-refractory local recurrences was constructed and used for immunohistochemical detection of protein expression. Results: Among 5184 genes surveyed with cDNA Microarray Technology, expression of 37 (0.7%) was increased more than twofold in the hormone-refractory CWR22R xenografts compared with the CWR22 xenograft ; expression of 135 (2.6%) genes was reduced by more than 50%. The genes encoding insulin-like growth factor-binding protein 2 (IGFBP2) and 27-kd heat-shock protein (HSP27) were among the most consistently over-expressed genes in the CWR22R tumors. Immunohistochemical analysis of tissue Microarrays demonstrated high expression of IGFBP2 protein in 100% of the hormone-refractory clinical tumors, in 36% of the primary tumors, and in 0% of the benign prostatic specimens (two-sided P = .0001). Overexpression of HSP27 protein was demonstrated in 31% of the hormone-refractory tumors, in 5% of the primary tumors, and in 0% of the benign prostatic specimens (two-sided P = .0001). Conclusions: The combination of cDNA and tissue Microarray technologies enables rapid identification of genes associated with progression of prostate cancer to the hormone-refractory state and may facilitate analysis of the role of the encoded gene products in the pathogenesis of human prostate cancer.
Erwin P. Bottinger - One of the best experts on this subject based on the ideXlab platform.
-
Genetic/genomic analysis of signal transduction pathways using cDNA Microarray Technology
Nature Genetics, 1999Co-Authors: Yaw-ching Yang, Ester Piek, Aldo Massimi, Rongguang Yang, Joerg Heyer, Raju Kucherlapati, Anita B. Roberts, Erwin P. BottingerAbstract:cDNA Microarray Technology provides a novel approach to identify individual target genes and survey global genetic programs under the control of specific signalling pathways in mammalian systems. Smad2 and Smad3 are highly homologous members of the receptor-regulated subfamily of Smad proteins with a central role in TGF- signalling and target gene regulation.
-
genetic genomic analysis of signal transduction pathways using cDNA Microarray Technology
Nature Genetics, 1999Co-Authors: Yaw-ching Yang, Ester Piek, Aldo Massimi, Rongguang Yang, Joerg Heyer, Raju Kucherlapati, Anita B. Roberts, Erwin P. BottingerAbstract:cDNA Microarray Technology provides a novel approach to identify individual target genes and survey global genetic programs under the control of specific signalling pathways in mammalian systems. Smad2 and Smad3 are highly homologous members of the receptor-regulated subfamily of Smad proteins with a central role in TGF- signalling and target gene regulation.
Lukas Bubendorf - One of the best experts on this subject based on the ideXlab platform.
-
hormone therapy failure in human prostate cancer analysis by complementary dna and tissue Microarrays
Journal of the National Cancer Institute, 1999Co-Authors: Lukas Bubendorf, Yidong Chen, Meelis Kolmer, Juha Kononen, Pasi A Koivisto, Spyro Mousses, Eija Mahlamaki, Peter Schraml, Holger MochAbstract:Background: The molecular mechanisms underlying the progression of prostate cancer during hormonal therapy have remained poorly understood. In this study, we developed a new strategy for the identification of differentially expressed genes in hormone-refractory human prostate cancer by use of a combination of complementary DNA (cDNA) and tissue Microarray technologies. Methods: Differences in gene expression between hormone-refractory CWR22R prostate cancer xenografts (human prostate cancer transplanted into nude mice) and a xenograft of the parental, hormone-sensitive CWR22 strain were analyzed by use of cDNA Microarray Technology. To validate the data from cDNA Microarrays on clinical prostate cancer specimens, a tissue Microarray of specimens from 26 prostates with benign prostatic hyperplasia, 208 primary prostate cancers, and 30 hormone-refractory local recurrences was constructed and used for immunohistochemical detection of protein expression. Results: Among 5184 genes surveyed with cDNA Microarray Technology, expression of 37 (0.7%) was increased more than twofold in the hormone-refractory CWR22R xenografts compared with the CWR22 xenograft ; expression of 135 (2.6%) genes was reduced by more than 50%. The genes encoding insulin-like growth factor-binding protein 2 (IGFBP2) and 27-kd heat-shock protein (HSP27) were among the most consistently over-expressed genes in the CWR22R tumors. Immunohistochemical analysis of tissue Microarrays demonstrated high expression of IGFBP2 protein in 100% of the hormone-refractory clinical tumors, in 36% of the primary tumors, and in 0% of the benign prostatic specimens (two-sided P = .0001). Overexpression of HSP27 protein was demonstrated in 31% of the hormone-refractory tumors, in 5% of the primary tumors, and in 0% of the benign prostatic specimens (two-sided P = .0001). Conclusions: The combination of cDNA and tissue Microarray technologies enables rapid identification of genes associated with progression of prostate cancer to the hormone-refractory state and may facilitate analysis of the role of the encoded gene products in the pathogenesis of human prostate cancer.